ATF2 and melanoma: In agreement with our findings, Z. Ronai and collaborators have demonstrated the ability of a 51-residue polypeptide derived from the ATF2 transactivating domain (ATF250–100) to alter melanoma growth and metastasis capacity in vivo[12], [54], [55].